Construction of the facility is projected to be completed by 2025, with the first clinical trials scheduled to commence in spring 2026
Irvine, Calif., and Bydgoszcz, Poland, June XX, 2023 – TAE Life Sciences, a global leader in advanced biological-targeted radiation therapy, and creator of next-genera on boron neutron capture therapy (BNCT) systems, and the Franciszek Łukaszczyk Oncology Center (FLOC) are proud to announce their collaboration to establish a cu ng-edge Boron Neutron Capture Therapy (BNCT) Center in Bydgoszcz, Poland. This groundbreaking radiation therapy facility will utilize TAE Life Sciences’ AlphaBeam® BNCT system to provide targeted treatment to patients with particularly challenging forms of cancer, including brain tumors.
BNCT is an innovative radiotherapy technique that offers a significant advantage over conventional methods by minimizing the negative effects on healthy tissues. By selectively targe ng cancer cells while preserving surrounding healthy tissue, BNCT shows immense promise in improving patient outcomes.
“We are honored to be the second center in Europe to implement the TAE Life Sciences BNCT groundbreaking treatment method,” emphasized Marshal Piotr Całbecki. “For many patients, this represents a chance for life-saving treatment and renewed hope.”
During the signing ceremony held on June 16th, Prof. Janusz Kowalewski, the director of the Franciszek Łukaszczyk Oncology Center, highlighted the importance of this modern and safe therapy. “BNCT is already successfully used in Japan, China, and Taiwan, and soon it will be introduced in Italy as well. FLOC’s partnership with TAE Life Sciences is a testament to Poland’s commitment to providing exceptional healthcare. Furthermore, this new center will greatly enhance our center’s scientific potential.”
The future BNCT Center at the Franciszek Łukaszczyk Oncology Center will serve as a leading research and therapeutic facility, conducting meticulous clinical trials. By joining the elite global network of BNCT centers, FLOC will initially focus on treating the most challenging malignant brain, head, and neck tumors, with plans to expand its scope to other types of cancer. The construction of the facility is projected to be completed by 2025, with the first clinical trials scheduled to commence in spring 2026.
This collaborative endeavor between TAE Life Sciences and FLOC represents a significant step forward in cancer treatment and demonstrates the commitment to advancing medical innovation in Poland. Together, they aim to provide a new ray of hope for patients battling the most challenging forms of cancer.
For more information about TAE Life Sciences, Alphabeam, and the company’s proprietary boronated BNCT drugs, please visit taelifesciences.com.
About TAE Life Sciences
TAE Life Sciences is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TAE Life Sciences is the only company developing the next-generation targeted boron drugs and low-energy accelerator-based neutron system optimized for an in-hospital BNCT program that delivers cancer-killing radiation with cellular-level precision to treat patients with aggressive and refractory cancers. TAE Life Sciences’ Alphabeam neutron system and targeted boron drugs are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at taelifesciences.com.
About FLOC
The Franciszek Łukaszczyk Oncology Center (FLOC) in Bydgoszcz is a modern hospital at the forefront of cancer treatment in Poland. It is renowned for its exceptional care, continuous modernization efforts, and commitment to scientific advancement. FLOC is managed by the local government of the Kujawsko-Pomorskie voivodeship and is part of a broader healthcare network serving the region.
